Home › Kidney Cancer (Renal Cell Carcinoma) › NCT07038733
Investigation of Lymph Node Biology in Kidney Cancer
Characterizing the Tumor-draining Lymph Nodes and Other Immune Sites in Renal Cell Carcinoma
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Candidates for inclusion include adult patients with either a known or suspected kidney cancer referred to Yale Genitourinary Oncology providers in the Yale Urology, Medical Oncology and Radiation Oncology or Nephrology Departments. These individuals will be receiving clinical evaluation/medical treatment/surgery/procedures at Yale New Haven Hospital or the Smilow Cancer Hospital. Participant eligibility will be determined by study investigators and will be offered protocol details. Interested participants will be invited to participate by study investigators. Consent will be obtained by study investigators or other authorized study personnel. Any potential adult participants with known or suspected kidney cancers with a renal mass who are patients of non-study physicians will be invited to participate by study personal only with the approval of their treating physician. Exclusion Criteria * Participants under the age of 18. Children will not be enrolled on the study. * Participants known to be pregnant or actively breastfeeding. * Iodine allergy hypersensitivity.
About the study
The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. Investigators will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.
What is being tested
- Peripheral Blood Sample for Immune Analysis (procedure)
- Tumor Sample for Analysis (procedure)
- Adjacent non-malignant kidney for analysis (procedure)
- Draining lymph node(s) for analysis (procedure)
- Regional non-draining lymph node(s) for analysis (procedure)
Sponsor: Yale University · Participants: 33 · Started: Jan 30, 2026
Contact the study team
- Stephanie Ladd · Phone: 954-895-0576
Official record on ClinicalTrials.gov — NCT07038733
Locations in the U.S.
| Connecticut | Yale University, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.